CLINCAL RESEARCH STUDY FOR  ADRENOCORTICAL CANCER (acc)

Corcept Therapeutics is now looking for volunteers to participate in a clinical study of the investigational
study drug, relacorilant, in combination with the immunotherapy drug, Keytruda® (pembrolizumab). See details here: 
nadf_acc_clinical_study.pdf

Corcept Therapeutics is committed to improving patient lives through the discovery and development of drugs that address serious unmet medical needs related to excess cortisol activity.  Visit www.Corcept.com for more information.

---